H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $60.00 price target on Capricor Therapeutics (NASDAQ: CAPR)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments